Literature DB >> 17868729

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Wassim Kassouf1, Ricardo Sanchez-Ortiz, Pheroze Tamboli, Nizar Tannir, Eric Jonasch, Madhur M Merchant, Surena Matin, David A Swanson, Christopher G Wood.   

Abstract

PURPOSE: To our knowledge the benefit of cytoreductive surgery for patients with metastatic renal cell carcinoma with nonclear cell histology is unknown. In this retrospective study we report our experience with cytoreductive nephrectomy for nonclear cell metastatic renal cell carcinoma at M. D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma.
MATERIALS AND METHODS: From 1991 to 2006, 606 patients with metastatic renal cell carcinoma underwent cytoreductive nephrectomy and they formed the basis of this report. Of these patients 92 had nonclear cell metastatic renal cell carcinoma. The remaining 514 patients had clear cell metastatic renal cell carcinoma and they formed a comparative group. Multivariate Cox regression analysis was performed to evaluate the relationship between clinical variables and histology (clear cell vs nonclear cell) on disease specific survival.
RESULTS: Compared with patients with clear cell histology those with nonclear cell metastatic renal cell carcinoma were younger (p = 0.0001), and more likely to have nodal metastases (p <0.0001) and sarcomatoid features (23% vs 13%, p = 0.026). On multivariate analysis median disease specific survival in patients with nonclear cell histology was significantly worse than that in patients with clear cell metastatic renal cell carcinoma (9.7 vs 20.3 months, p = 0.0003) even after adjusting for T stage, grade, performance status, age and sarcomatoid features. Sarcomatoid features were a predictor of poor outcome in cases of clear and nonclear cell histology, although even in the absence of sarcomatoid features nonclear cell histology was associated with worse disease specific survival (p = 0.017). Interestingly although there was a significantly higher incidence of positive nodes in patients with nonclear histology (p <0.0001), this phenotype was not associated with a worse disease specific survival, as it was in those with clear cell histology (p = 0.0001). In fact, patients with node negative disease with nonclear cell histology had the worst prognosis overall in the entire group.
CONCLUSIONS: Patients with nonclear cell metastatic renal cell carcinoma were younger and had a higher incidence of nodal metastases, a higher incidence of sarcomatoid features and a worse prognosis than those with clear cell histology who underwent cytoreductive surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17868729     DOI: 10.1016/j.juro.2007.07.037

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

Authors:  E Jason Abel; Christopher G Wood
Journal:  Nat Rev Urol       Date:  2009-06-16       Impact factor: 14.432

2.  Impact of tyrosine kinase inhibitors and cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Authors:  Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

3.  Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Authors:  Ross J Mason; Lori Wood; Anil Kapoor; Naveen Basappa; George Bjarnason; Stephen A Boorjian; Rodney H Breau; Ilias Cagiannos; Michael A S Jewett; Pierre I Karakiewicz; Wassim Kassouf; Christian Kollmannsberger; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Luke T Lavallée; Stephen Pautler; Nicholas Power; Patrick Richard; Alan So; Simon Tanguay; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

Review 4.  Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Laura-Maria Krabbe; Ahmed Q Haddad; Mary E Westerman; Vitaly Margulis
Journal:  World J Urol       Date:  2014-04-04       Impact factor: 4.226

Review 5.  Management of Atypical Renal Cell Carcinomas.

Authors:  Bobby C Liaw; Reza Mehrazin; Charles Baker; John P Sfakianos; Che-Kai Tsao
Journal:  Curr Treat Options Oncol       Date:  2017-09-14

6.  Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).

Authors:  Ayal A Aizer; Yuksel Urun; Rana R McKay; Adam S Kibel; Paul L Nguyen; Toni K Choueiri
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

Review 7.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

8.  Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.

Authors:  E Jason Abel; Stephen H Culp; Surena F Matin; Pheroze Tamboli; Michael J Wallace; Eric Jonasch; Nizar M Tannir; Christopher G Wood
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

Review 9.  Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.

Authors:  Vitaly Margulis; Christopher G Wood; Eric Jonasch; Surena F Matin
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

10.  Clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinoma.

Authors:  Yi Yan; Longfei Liu; Jingyu Zhou; Liling Li; Yuan Li; Minfeng Chen; Long Wang; Wei He; Xiao Guan; Xiongbing Zu; Lin Qi
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.